Russian scientists have submitted a drug for the treatment and prevention of atherosclerosis for registration to the Ministry of Health. This was announced by Elena Ponomarenko, acting director of the V. N. Orekhovich Research Institute of Biomedical Chemistry. According to her, the drug normalizes lipid metabolism and has an anti-atherosclerotic effect.
The domestically developed drug enhances the natural excretion of excess cholesterol from cells and plaques without interfering with metabolism. It is based on phospholipid nanoparticles less than 100 nm in size. They help high-density lipoproteins bind and remove 'bad' cholesterol.
What the trials showed
The drug passed Phase II–III clinical trials. It was tested on patients with elevated triglycerides and reduced 'good' cholesterol. 100 people participated in the study, and the treatment lasted 12 weeks.
Result: a 13.2% reduction in non-HDL-C versus 4.3% in the placebo group. Triglycerides decreased by 0.7 mmol/L versus 0.1 mmol/L in the placebo group. The trials were conducted at the Chazov National Medical Research Center of Cardiology, Nizhny Novgorod Regional Hospital, and Yaroslavl Clinical Hospitals.